AstraZeneca Pharma India Limited has received a permission in Form CT-20 to Import for sale and distribution of Trastuzumab deruxtecan (Enhertu) 100mg/5mL vial lyophilized powder.
The Board of Directors of AstraZeneca Pharma India Limited have approved the financial results of the company for the period ended December 31, 2022 - Q3FY23, 9MFY23 at its board meeting.
AstraZeneca Pharma India Ltd has received an Import and Market permission in Form CT-20 from the CDSCO , Directorate General of Health Services, Government of India for Dapagliflozin i.e., Forxiga® tablets of 10 mg - additional indication.